Signaling of angiotensin II-induced vascular protein synthesis in conduit and resistance arteries in vivo

BMC Cardiovascular Disorders

Pierre Moreau¹  Rhian M Touyz²  Huy Hao Dao¹  Daphné Girardot¹  Fabrice MAC Martens¹  Christine Daigle¹ 

[1] Faculty of Pharmacy, Université de Montréal, PO Box 6128, Station centre-ville, Montréal, Québec, H3C 3J7 Canada;Institut de Recherches Cliniques de Montréal, 110 ave des Pins ouest,Montréal, Québec, H2W 1R7 Canada

关键词: ERK-1/2;    Rapamycin;    Conduit arteries;    Resistance arteries;    Remodeling;   

Others  :  1088603
DOI  :  10.1186/1471-2261-4-6

 received in 2004-03-04, accepted in 2004-05-10,  发布年份 2004

【 摘 要 】

Background

From in vitro studies, it has become clear that several signaling cascades are involved in angiotensin II-induced cellular hypertrophy. The aim of the present study was to determine some of the signaling pathways mediating angiotensin II (Ang II)-induced protein synthesis in vivo in large and small arteries.

Methods

Newly synthesized proteins were labeled during 4 hours with tritiated leucine in conscious control animals, or animals infused for 24 hours with angiotensin II (400 ng/kg/min). Hemodynamic parameters were measure simultaneously. Pharmacological agents affecting signaling cascades were injected 5 hours before the end of Ang II infusion.

Results

Angiotensin II nearly doubled the protein synthesis rate in the aorta and small mesenteric arteries, without affecting arterial pressure. The AT₁ receptor antagonist Irbesartan antagonized the actions of Ang II. The Ang II-induced protein synthesis was associated with increased extracellular signal-regulated kinases (ERK)1/2 phosphorylation in aortic, but not in mesenteric vessels. Systemic administration of PD98059, an inhibitor of the ERK-1/2 pathway, produced a significant reduction of protein synthesis rate in the aorta, and only a modest decrease in mesenteric arteries. Rapamycin, which influences protein synthesis by alternative signaling, had a significant effect in both vessel types. Rapamycin and PD98059 did not alter basal protein synthesis and had minimal effects on arterial pressure.

Conclusion

ERK1/2 and rapamycin-sensitive pathways are involved in pressure-independent angiotensin II-induced vascular protein synthesis in vivo. However, their relative contribution may vary depending on the nature of the artery under investigation.

【 授权许可】

   
2004 Daigle et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured vascular smooth muscle cells. Circulation Research 1988, 62:749-756.
• [2]Simon G, Illyes G, Csiky B: Structural vascular changes in hypertension: role of angiotensin II, dietary sodium supplementation, blood pressure and time. Hypertension 1998, 32:654-660.
• [3]Moreau P, d'Uscio LV, Takase H, Shaw S, Barton M, Lüscher TF: Angiotensin II increases tissue endothelin and induced vascular hypertrophy in vivo: reversal by ETA-receptor antagonist. Circulation 1997, 96:1593-1597.
• [4]Griffin SA, Brown WCB, Macpherson F, McGrawth JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF: Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991, 17:626-635.
• [5]Kato H, Hou J, Chobanian AV, Brecher P: Effects of angiotensin II infusion and inhibition of nitric oxyde synthase on the rat aorta. Hypertension 1996, 28:153-158.
• [6]Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circulation Research 1991, 68:450-456.
• [7]Berk BC: Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. Journal of the American Society of Nephrology 1999, 10:S62-S68.
• [8]Sonenberg N, Gingras AC: The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998, 10:268-275.
• [9]Servant MJ, Giasson E, Meloche S: Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. Journal of Biological Chemistry 1996, 271:16047-16052.
• [10]Giasson E, Meloche S: Role of P70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. Journal of Biological Chemistry 1995, 270:5225-5231.
• [11]Sadoshima J, Izumo S: Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circulation Research 1995, 77:1040-1052.
• [12]Tsuda T, Kawahara Y, Ishida Y, M. Koide., K. Shii., Yokoyama M: Angiotensin II stimulates two myelin basic protein/microtubular associated protein 2 kinases in cultured vascular smoothe muscle cells. Circulation Research 1992, 71:620-630.
• [13]Alessi DR, Cuenda A, Cohen P, Dudley DT, Salteil AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Journal of Biological Chemistry 1995, 270:27489-27494.
• [14]Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Nat Acad Sci U.S.A 1995, 92:7686-7689.
• [15]Proud CG: p70 S6 kinase: an enigma with variations. Trends in Biological Sciences 1996, 21:181-185.
• [16]Moreau P, Lamarche L, K.-Laflamme A, Yamaguchi N, de Champlain J: Chronic hyperinsulinemia and hypertension: the role of the sympathetic nervous system. Journal of Hypertension 1995, 13:333-340.
• [17]McNulty PH, Young LH, Barrett EJ: Response of the rat heart and skeletal muscle protein in vivo to insulin and amino acid infusion. American Journal of Physiology 1993, 264:E958-E965.
• [18]Voisin L, Foisy S, Giasson E, Moreau P, Meloche S: EGF receptor transactivation is obligatory for protein synthesisstimulation by G protein-coupled receptors. Am J Physiol Cell Physiol 2002, 83:C446-55.
• [19]Martens FMAC, Demeilliers B, Girardot D, Daigle C, Dao HH, deBlois D, Moreau P: Vessel specific stimulation of protein synthesis by nitric oxide synthase inhibition: role of extracellular regulated kinases 1/2. Hypertension 2002, 39:16-21.
• [20]Lowry OH, Rosenbrough NJ, Lewis Far A, Randall RJ: Protein measurement with the folin-phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
• [21]Touyz RM, Deng LY, He G, Wu HH, Schiffrin EL: Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. Journal of Hypertension 1999, 17:907-916.
• [22]Su EJ, Lombardi DM, Siegal J, Schwartz SM: Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998, 31:1331-1337.
• [23]Simon G, Altman S: Subpressor angiotensin II is a bifunctional growth factor of vascular muscle in rats. Journal of Hypertension 1992, 10:1165-1171.
• [24]Matrougui K, Eskildsen-Helmond A, Fiebeler A, Henrion D, Levy BI, Tedgui A, Mulvany MJ: Angiotensin II stimulates extracellular signal-regulated kinase activity in intact pressurized rat mesenteric arteries. Hypertension 2000, 36:617-621.
• [25]Rao GN, Griendling KK, Frederickson RM, Sonenberg N: Angiotensin II induces phosphorylation of eukaryotic protein synthesis initiation factor 4E in vascular smooth muscle cells. Journal of Biological Chemistry 1994, 269:7180-7184.
• [26]von Manteuffel SR, Gingras A-C, Ming X-F, Sonenberg N, Thomas G: 4E-BP1 phosphorylation is mediated by the FRAP-p70S6k pathway and is independent of mitogen-activated protein kinase. Proceedings of the National Academy of Science of the USA 1996, 93:4076-4080.
• [27]Jefferies HBJ, Thomas G: Ribosomal protein S6 phosphorylation and signal transduction. In Translational Control. Edited by Hershey JWB, Mathews MB and Sonenberg N. Cold Spring Harbor, Cold Spring Harbor Laboratory Press; 1996:389-410.
• [28]Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, Marumo F, Hirata Y, Inagami T: Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. Journal of Biological Chemistry 1999, 274:36843-36851.
• [29]Herbert JM, Delisee C, Dol F, Schaeffer P, Cazaubon C, Nisato D, Chatelain P: Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. European Journal of Pharmacology 1994, 251:143-150.
• [30]Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B, et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 1993, 265:826-834.
• [31]Wu L, Iwai M, Nakagami H, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M: Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arteriosclerosis, Thrombosis and Vascular Biology 2002, 22:49-54.
• [32]Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, Xia Z: Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 2001, 21:434-443.
• [33]Kim S, Murakami T, Izumi Y, Yano M, Miura K, Yamanaka S, Iwao H: Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activities are continuously and differentially increased in aorta of hypertensive rats. Biochemical and Biophysical Research Communications 1997, 236:199-204.
• [34]Girardot D, Demeilliers B, deBlois D, Moreau P: ERK1/2-mediated vasoconstriction normalizes wall stress in small mesenteric arteries during NOS inhibition in vivo. J Cardiovasc Pharmacol 2003, 42:339-347.